{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-000860","form_type":"8-K","ticker":"AZTA","cik":"0000933974","company_name":"Azenta, Inc.","filed_at":"2024-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.348930+00:00","generated_at":"2026-06-06T07:35:53.307067+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Azenta Q1 rev $154M (-13% YoY), GAAP EPS ($0.28), non-GAAP $0.02; reaffirms FY24 guide","bullets":["Revenue $154M, down 13% YoY; organic revenue -15%; combined Sample Mgmt & Multiomics grew 2% organic.","GAAP diluted EPS from continuing ops ($0.28) vs ($0.15) prior year; non-GAAP diluted EPS $0.02 vs $0.12.","B Medical revenue $13M, down 70% YoY (timing of orders); Sample Mgmt Solutions up 5%, Multiomics up 3%.","FY2024 guidance reaffirmed: total revenue $696-$718M, non-GAAP EPS $0.19-$0.29, adj EBITDA margin +300bps.","Repurchased 2.3M shares for $113M in Q1; plans additional $500M in FY2024 to complete $1.5B authorization."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-000860","json":"https://secwatch.observer/filing/0001558370-24-000860.json","markdown":"https://secwatch.observer/filing/0001558370-24-000860.md","text":"https://secwatch.observer/filing/0001558370-24-000860.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/933974/000155837024000860/0001558370-24-000860-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/933974/000155837024000860/azta-20240207x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T07:35:53.307067+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bc7bddf95153862e62f2329f6726a9d7c2eca855","claim":"Azenta, Inc. reported the first quarter ended December 31, 2023 results: revenue $ 154, net income $ (0.28), EPS $(0.28) per diluted share. Guidance reaffirmed.","evidence_excerpt":"in millions, except per share data ​ December 31, ​ September 30, ​ December 31, ​ Change ​ ​ 2023 ​ 2023 ​ 2022 ​ Prior Qtr ​ Prior Yr. Revenue from Continuing Operations $ 154 ​ $ 172 $ 178 ​ (10) % ​ (13) % Organic growth ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (15) % Sample Management Solutions ​ $ 79 ​ $ 82 ​ $ 75 ​ (3) % ​ 5 % Multiomics ​ $ 63 ​ $ 61 ​ $ 61 ​ 3","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/933974/000155837024000860/0001558370-24-000860-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended December 31, 2023"},{"label":"Revenue","value":"$ 154"},{"label":"Net income","value":"$ (0.28)"},{"label":"EPS","value":"$(0.28) per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}